All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Frederick Locke, Moffitt Cancer Center, Tampa, US. We asked, Is ALLO-501A a promising alternative to autologous CAR T-cells?
ALPHA2: Is ALLO-501A a promising alternative to autologous CAR T-cells?
ALLO-501A is an off-the-shelf, anti-CD19 allogeneic CAR T-cell therapy which is gene edited to disrupt the TCRα gene to reduce GvHD risk, as well as the CD52 gene to allow the use of ALLO-647, an anti-CD52 mAb, for lymphodepletion without affecting grafted CAR T-cells. Locke evaluates safety and efficacy results from the phase II ALPHA2 trial, investigating ALLO-647 in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
ALPHA study: First-in-human data of ALLO-501 and ALLO-647 in R/R large B-cell or follicular lymphoma
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to Sattva Neelapu, MD Anderson Cancer...
Results from the ALPHA study on ALLO-501 and lymphodepleting ALLO-647 in R/R DLBCL or FL
The ALPHA study is a first-in-human phase I trial (NCT03939026) of ALLO-501 and ALLO-647 for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) or...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox